coronary artery disease
Conditions
Interventions
Group 1:trimetazidine
Group 2:placebo
Sponsors
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. CAD patients with hypertensive LVH who received PCI. Hypertensive LVH is defined by left ventricular mass index (LVMI); 2. Male and female adults aged 18-70 years; 3. Coronary stenosis > 70% before PCI performed, and < 20% after PCI, with no need for angioplasty; 4. Trimetazidine naive; 5. Provision of informed consent prior to any study specific procedures.
Exclusion criteria
Exclusion criteria: 1. Patients with utilization of trimetazidine, coenzyme Q10 or other medications which would affect cardiac metabolism; 2. Concomitant with other causes for left ventricular hypertrophy, such as aortic constriction, hypertrophic cardiomyopathy and cardiac valvular disease; 3. Concomitant with other causes for myocardial ischemia, such as congenital heart disease, rheumatic heart disease, dilated cardiomyopathy; 4. Patients with severe pulmonary, liver and kidney dysfunction; 5. Patients with heart function classified as New York Heart Association III-IV; 6. Patients with atrial fibrillation; 7. Patients with previous or current cancer; 8. Patients with positive pregnancy test, lactating women and women of child-bearing potential not to use appropriate contraceptive measures; 9. Patients with life expectancy of 12 months or less.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| left ventricular mass index; | — |
Secondary
| Measure | Time frame |
|---|---|
| major adverse cardiovascular events;NT-proBNP;6-minute walking test;Symptoms of angina;exercise electrocardiography test; | — |
Countries
China
Contacts
Public ContactWenbin Zhang
Department of Cardiology, Biomedical Research (Therapy) Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang, China
Outcome results
None listed